Premila Leiphrakpam,Chandrakanth Are,Premila D. Leiphrakpam
Abstract:In the last decade, pathway-specific targeted therapy has revolutionized colorectal cancer (CRC) treatment strategies. This type of therapy targets a tumor-vulnerable spot formed primarily due to an alteration in an oncogene and/or a tumor suppressor gene. However, tumor heterogeneity in CRC frequently results in treatment resistance, underscoring the need to understand the molecular mechanisms involved in CRC for the development of novel targeted therapies. The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of the rapamycin (PI3K/Akt/mTOR) signaling pathway axis is a major pathway altered in CRC. The aberrant activation of this pathway is associated with CRC initiation, progression, and metastasis and is critical for the development of drug resistance in CRC. Several drugs target PI3K/Akt/mTOR in clinical trials, alone or in combination, for the treatment of CRC. This review aims to provide an overview of the role of the PI3K/Akt/mTOR signaling pathway axis in driving CRC, existing PI3K/Akt/mTOR-targeted agents against CRC, their limitations, and future trends.
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the role of the phosphatidylinositol 3 - kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway as a therapeutic target for colorectal cancer (CRC). Specifically, the paper aims to:
1. **Outline the role of the PI3K/Akt/mTOR signaling pathway in driving CRC**: Explain how this signaling pathway affects processes such as cell growth, survival, proliferation, and migration, and plays a crucial role in the occurrence, development, and metastasis of CRC.
2. **Summarize the existing PI3K/Akt/mTOR - targeted drugs and their limitations**: Introduce the currently clinically used PI3K/Akt/mTOR inhibitors for CRC treatment, including pan - PI3K inhibitors, specific subtype PI3K inhibitors, dual PI3K - mTOR inhibitors, Akt inhibitors, and mTOR inhibitors, and discuss the efficacy and side effects of these drugs.
3. **Look forward to future research trends**: Explore how to overcome the limitations of existing drugs through further research and development of new inhibitors, and improve the treatment effect and survival rate of CRC patients.
### Main content of the paper
#### 1. Introduction
- Colorectal cancer (CRC) is one of the major cancers causing high morbidity and mortality worldwide.
- Current treatment methods include surgery, chemotherapy, and radiotherapy, but the efficacy of these methods in patients with advanced CRC is limited.
- Targeted therapy against specific signaling pathways has become a new direction in CRC treatment, especially targeted therapy against the PI3K/Akt/mTOR signaling pathway.
#### 2. Overview of the PI3K/Akt/mTOR signaling pathway
- The PI3K/Akt/mTOR signaling pathway regulates multiple cellular processes in normal cells, such as cell survival, proliferation, growth, migration, metabolism, protein synthesis, transcription, apoptosis, and angiogenesis.
- The abnormal activation of this pathway is closely related to the occurrence, development, and metastasis of CRC, especially through the activation of RTKs and the mutation or amplification of key genes (such as PI3KCA, IRS1, PI3KR1, PDK1, AKT1, AKT2, PAK4, mTOR, PTEN, and TSC1/2).
#### 3. Alterations in the PI3K/Akt/mTOR pathway in CRC
- The PI3K/Akt/mTOR pathway is one of the most frequently altered pathways in human cancers.
- Common genetic alterations include missense mutations in the PIK3CA gene, loss - of - function mutations in the PTEN gene, amplification of the IRS2 gene, mutations in the PIK3R1 gene, etc.
- These genetic alterations lead to the abnormal activation of the PI3K/Akt/mTOR pathway, thereby promoting the survival, proliferation, and metastasis of CRC cells.
#### 4. Recent progress in the research of PI3K/Akt/mTOR inhibitors
- A variety of drugs targeting the PI3K/Akt/mTOR pathway are being evaluated in different stages of clinical trials, including pan - PI3K inhibitors, specific subtype PI3K inhibitors, dual PI3K - mTOR inhibitors, Akt inhibitors, and mTOR inhibitors.
- The paper details the clinical trial results of these drugs, including their efficacy, side effects, and future research directions.
### Conclusion
The paper emphasizes the importance of the PI3K/Akt/mTOR signaling pathway in CRC and points out that targeted therapy against this pathway has great potential. However, the existing targeted drugs still have some limitations, and future research needs to further optimize these drugs to improve their efficacy and safety.